# A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody

> **NCT07445815** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Lanzhou Institute of Biological Products Co., Ltd** · enrollment: 200 (estimated)

## Conditions studied

- Rabies (Healthy Volunteers)

## Interventions

- **DRUG:** Recombinant Human Rabies Virus Monoclonal Antibody Injection
- **DRUG:** Human Rabies Immunoglobulin (HRIG)
- **DRUG:** Placebo
- **BIOLOGICAL:** Rabies Vaccine

## Key facts

- **NCT ID:** NCT07445815
- **Lead sponsor:** Lanzhou Institute of Biological Products Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-31
- **Primary completion:** 2026-07-29
- **Final completion:** 2026-08-21
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07445815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07445815, "A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07445815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*